Effect of Semaglutide and Tirzepatide Combined With Exercise in Obesity

Sponsor
Istanbul Galata University
Study ID
NCT07319975
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
25 Years - 60 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

Obesity is a growing global health problem that affects people of all ages. It can lead to serious health issues such as cardiovascular disease, insulin resistance, inflammation, and reduced physical function. New medications, including GLP-1 receptor agonists like semaglutide and dual GLP-1/GIP agonists like tirzepatide, have been shown to help people lose significant weight. However, some of this rapid weight loss may come from a reduction in muscle mass rather than fat. Losing muscle can lower physical performance, impair metabolic health, and increase the risk of developing sarcopenic obesity. This study aims to compare the effects of pharmacological treatment alone with a combined treatment program that includes both medication and exercise in individuals with obesity. The primary objective is to evaluate how these two approaches influence body composition. The secondary objective is to examine the effects of pharmacological treatment versus combined treatment on cardiometabolic markers, peripheral muscle strength, functional capacity, respiratory function, respiratory muscle performance, and physical activity levels. The study seeks to determine whether adding structured exercise to medication can provide additional health benefits beyond weight loss.

Key Dates

Start date
Dec 29, 2025
Status verified
Dec 2025
Primary completion
Oct 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
48 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: ARM 1-Semaglutide
    Drug: Semaglutide
  • Experimental: ARM 3-Semaglutide + Exercise
  • Experimental: ARM 4-Tirzepatide + Exercise
  • Experimental: ARM 2-Tirzepatide
    Drug: Tirzepatide

Primary Outcome Measure

Body fat-muscle ratios (Body composition) [ Time Frame: Three months ]

Central Contacts

Related Studies